A Phase 1/2, First-in-Human, Multicenter, Open-Label Study of SQZ-eAPC-HPV as Monotherapy and in Combination with Immune Checkpoint Inhibitor(s) in Patients with HPV16+ Recurrent, Locally Advanced, or Metastatic Solid Tumors
Details
Age
Adult
Eligibility
Histologically confirmed incurable or metastatic solid tumor (including but not limited to cervical and head and neck tumors) that are HPV16+ as determined by histological or HPV16 molecular analysis.
Type of Study
Treatment
Locations
CTRC Inpatient
University of Colorado Hospital
Principal Investigator
Antonio Jimeno, MD, PhD
Study ID
Protocol Number: 22-0228
More information available at ClinicalTrials.gov: NCT05357898
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers